2019 Cannabis Business Award's Publication of the Year |
WEDNESDAY, OCTOBER 14, 2026 |
FMCPG HAS BEEN SERVING
AND REPRESENTING THE CANNABIS PHYSICIAN COMMUNITY SINCE 2020 |
THE
"FLORIDA MEDICAL CANNABIS PHYSICIAN GROUP" (FMCPG) FOR ALL "MEDICAL MARIJUANA DOCTORS"
AND "MMTC DIRECTORS ONLY "
HOW TO HANDLE NEW PATIENT RENEWALS WITH THE STATE
CONTINUED DISCUSSION ON THE RESCHEDULING OF CANNABIS BY THE FEDERAL GOVT
REVIEW OF THE OMMU AND CHANGES TO THE DOCTOR'S AND PATIENT INPUT PORTALS ON THE OMMU WEBSITE.
DOCTORS WITHIN OUR GROUP WILL DISCUSS HOW THEY HAVE BEEN WORKING AROUND SOME OF THE CHANGES
REF'S ISSUES AND SOLUTIONS
TIME TO RENEW YOUR MEMBER IN FMCPG
CLICK HERE FOR THE MEMBERSHIP FORM USE THIS LINK TO REGISTER FOR THE NEXT MEETING - WEDNESDAY,
OCTOBER 14, 2026
CLICK ON LINK BELOW |
MEDICAL CANNABIS PHYSICIAN PROMOTION PACKAGE FOR 2026 BY CANNABIS NEWS FLORIDA
ARTICLE: Physician will contribute an article of 350 words**. This article will appear in the Cannabis News Florida e-newsletter for one month (4 weeks).
E-MAIL BLAST: Cannabis News Florida will send out one e-mail blast promoting the Physician to the other physicians in three zip code areas or one city to be determined by the Physician. The Physician will supply the information for the email blast. The Article above can be used in the e-mail blast.
The cost of this program is ONLY $499 AND INCLUDES A ONE YEAR MEMBERSHIP IN THE FMCPG - MUST BE PUCHASED BEFORE 12/31/26 **Cannabis News Florida will assign a writer for a telephone interview with the Physician and create the article to be published. Physician shall have the right to review and approve the article before publication for an additional cost of $100. IF YOU ARE INTERESTED, PLEASE EMAIL ME AT CHARLES@CANNABISNEWSFLORIDA.COM OR CALL MY CELL AT 954-605-4785 |
We want to apologize for the inconvenience caused by the recent technical issues affecting our ability to provide the current news updates, announcements, press releases, and information you rely on from the Florida Cannabis community.
As a result of these website-related issues, some of the latest news and updates have been delayed from appearing as scheduled in the Cannabis News Florida E-Newsletter.
Once the issues have been resolved, we will work to ensure that delayed news and updates are posted and shared with our readership.
We sincerely appreciate your patience, support, and understanding as we work through this unexpected interruption. Sometimes even the best systems need a little medical attention!
Thank you for being a valued reader of Cannabis News Florida E-Newsletter. We look forward to bringing you the latest news and information from Florida’s Cannabis community again very soon.
Thank you for your continued support and understanding. |
NEWS FROM THE PAST WEEK
RELATING TO THE BUSINESS OF MMTC'S
IN FLORIDA Click on Company Logo to be Transferred to Web Site
|
Trulieve Repays $65 Million Mortgage Strengthening Balance Sheet
TALLAHASSEE, Fla., Oct. 7, 2026 — Trulieve Cannabis Corp. (NYSE: TRLV) (“Trulieve” or “the Company”), a leading and top-performing medical cannabis company in the U.S., today announced the full repayment of an approximately $65 million mortgage notes payable secured by a cultivation site in Jefferson County, Florida, thereby reducing outstanding debt to approximately $225 million.
“We used our strong cash generation to repay this mortgage prior to its maturity date as part of our long term strategy to bolster our financial position,” said Trulieve CEO Kim Rivers. “Reducing balance sheet leverage lowers our annual interest expense, improving profitability and cash flow. Given the strength of our platform, we are well positioned to fund growth initiatives in the near term including expansion in Georgia and Texas, pending regulatory approvals.”
READ MORE
|
Curaleaf Enhances Offer to Acquire Aurora Cannabis
Increases total implied consideration by 25% to US$5.00 per Aurora Share, representing a premium of 86% to Aurora’s Unaffected Share Price
Increases Cash consideration by 33% to US$1.00 per Aurora Share, which represents approximately 20% of the consideration mix
Increases Share Consideration to 0.4013 Curaleaf shares per Aurora Share and increases the Cap Price by 20% to US$6.00 per share
Enhanced proposal developed solely from publicly available information; Curaleaf remains committed to engaging with Aurora in a formal due diligence process and urges Aurora’s Board to engage in good faith discussions regarding the Enhanced Offer
Enhanced Offer continues to provide Aurora Shareholders with the opportunity to become owners of the premium global cannabis platform and participate in the significant long-term upside of the combined company
STAMFORD, Conn., Oct. 5, 2026 — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company“), a leading international provider of consumer and medical cannabis products, today announced that it will file a Notice of Variation and Change to increase its offer (the “Enhanced Offer“) to acquire all of the issued and outstanding common shares (the “Aurora Shares“) of Aurora Cannabis Inc. (“Aurora“) for consideration consisting of subordinate voting shares of Curaleaf (the “Curaleaf Shares“) and cash.
Under the terms of the Enhanced Offer, Aurora shareholders would receive total implied consideration of US$5.00 per Aurora Share, comprised of 0.4013 Curaleaf Shares (the “Share Consideration“) plus US$1.00 cash (the “Cash Consideration“, and collectively with the Share Consideration, the “Amended Consideration“) based on Curaleaf’s U.S. dollar equivalent closing share price of C$14.21 (C$1.00 = US$0.7015) on October 2, 2026. Based on Aurora’s 30-day volume weighted average price (“VWAP“) of US$2.75 as of August 10, 2026 (the day before Curaleaf announced its intention to make its initial Offer (the “Unaffected Share Price“), the Enhanced Offer represents a premium of 86% to Aurora’s Unaffected Share Price. Excluding the value of the cash and cash equivalents that Aurora has on its balance sheet, including its subsequent equity issuances pursuant to its at-the-market (“ATM“) program issued during its fiscal first quarter, the Enhanced Offer represents a premium of 217% to the ex-cash Unaffected Share Price.
READ MORE
|
Curaleaf Files Update to Offering Circular
Curaleaf has filed a formal update to its Circular incorporating its previously announced increased Offer for Aurora
Curaleaf continues to call on Aurora to engage regarding its Offer and provide shareholders with a comprehensive view of the potential of the combined businesses
STAMFORD, Conn., Oct. 6, 2026 — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company“), a leading international provider of consumer and medical cannabis products, today announced that it has filed a Notice of Variation, Change and Extension (“Notice of Variation“) to increase its offer (the “Enhanced Offer“) to acquire all of the issued and outstanding common shares (the “Aurora Shares“) of Aurora Cannabis Inc. (“Aurora“) for consideration consisting of subordinate voting shares of Curaleaf (the “Curaleaf Shares“) and cash. The filing of the Notice of Variation follows through on Curaleaf’s announcement yesterday of its intent to make the Enhanced Offer.
Under the terms of the Enhanced Offer, Aurora shareholders would receive total implied consideration of US$5.00 per Aurora Share, comprised of 0.4013 Curaleaf Shares (the “Share Consideration“) plus US$1.00 cash (the “Cash Consideration“, and collectively with the Share Consideration, the “Amended Consideration“) based on Curaleaf’s U.S. dollar equivalent closing share price of C$14.21 (C$1.00 = US$0.7015) on October 2, 2026. Based on Aurora’s 30-day volume weighted average price (“VWAP“) of US$2.75 as of August 10, 2026 (the day before Curaleaf announced its intention to make its initial Offer (the “Unaffected Share Price“), the Enhanced Offer represents a premium of 86% to Aurora’s Unaffected Share Price. Excluding the value of the cash and cash equivalents that Aurora has on its balance sheet, including its subsequent equity issuances pursuant to its at-the-market (“ATM“) program issued during its fiscal first quarter, the Enhanced Offer represents a premium of 217% to the ex-cash Unaffected Share Price.
READ MORE |
Green Thumb Opens RISE Dispensary in Cape Coral, Expanding Florida Footprint to 25 Locations
RISE Dispensaries will serve medical patients in one of Southwest Florida’s fastest-growing, waterfront communities with the opening of RISE Dispensary Cape Coral, located at 928 NE Pine Island Road.
RISE Dispensary Cape Coral opens Oct. 10 and will celebrate its grand opening event on Saturday, Oct. 31 at 9:00 a.m. ET.
Continuing with RISE’s new store opening tradition, a portion of profits from RISE Dispensary Cape Coral’s grand opening will benefit local nonprofit The Grateful Veteran.
CHICAGO and VANCOUVER, British Columbia, Oct. 10, 2026 — RISE Dispensaries, an industry-leading cannabis retail chain owned by Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), today announced the opening of RISE Dispensary Cape Coral, Florida, on October 10. Located at 928 NE Pine Island Road, RISE Dispensary Cape Coral is Green Thumb’s 25th retail location in Florida, adding to the Company’s network of more than 120 stores nationwide.
Beginning October 10, RISE Dispensary Cape Coral will serve patients across Lee County with its best-in-class products and elite retail experience. The location will be open from 9:00 a.m. – 8:00 p.m. Monday through Saturday and from 11:00 a.m. – 6:00 p.m. ET Sunday.
RISE Dispensary Cape Coral will offer a broad assortment of products from Green Thumb’s portfolio, including RYTHM premium flower, full-spectrum vapes and concentrates, Dogwalkers pre-rolls, Good Green flower, &Shine flower and edibles, RISE flower and pre-rolls, Phat Panda flower and pre-rolls, Beboe edibles, and Doctor Solomon’s tinctures, RSO, and topicals.
READ MORE
|
INDIVA CANNABIS M&V Investment One LLC and its affiliates (collectively, “M&V”) and Royal Group Resources Ltd. (“RGR”). SEVEN LOCATION IN FLORIDA |
Cresco Labs Announces Filing of Supplement to Management Information Circular for Annual General and Special Meeting
October 9, 2026 – CHICAGO— Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company“) today announced that it has filed a supplement (the “Supplement“) to its management information circular dated September 18, 2026 (the “Circular“) in connection with its annual general and special meeting of shareholders to be held on October 30, 2026. The Supplement enhances and clarifies the disclosure in the Circular concerning the proposed amendment to Cresco’s super-voting shares and related minority approval requirements.
Additional Information and Where to Find It
The Supplement, the Circular and related materials are available under the Company’s profile on SEDAR+ at www.sedarplus.ca, under the Company’s profile on EDGAR at www.sec.gov, and on the Company’s website at www.crescolabs.com.
The Meeting is to be held at 12:00 p.m. (Central Daylight Time) on Friday, October 30, 2026, via live audio webcast. Shareholders of record as of the close of business on September 15, 2026, are entitled to receive notice of, and to vote at, the Meeting. Proxies must be received by 12:00 p.m. (Central Daylight Time) on Wednesday, October 28, 2026, or two business days before any adjourned or postponed Meeting. Beneficial shareholders who hold through an intermediary should follow the voting instructions provided by that intermediary, which may impose an earlier deadline.
READ MORE
|
CURRENTLY OWED BY VIREO GROWTH INC.
|
Vireo Growth Inc. to Acquire Planet 13 Holdings Inc. |
NATIONAL AND INTERNATIONAL NEWS |
Tilray Brands Delivers Record Q1 Fiscal 2027 Revenue and Record Q1 Gross Profit, Demonstrating the Power of Its Global Platform, Driven by Double-Digit Year-Over-Year Growth Across International Cannabis, Beverage and Pharmaceutical Distribution
First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum
Record First-Quarter Net Revenue of $257 Million, Up 23% Year-Over-Year, with Gross Margin Expanding by ~300 bps to 30%
International Business Accelerates as EMEA Revenue Increases 71%, Growth Led by Medical Cannabis, Beverage and Pharmaceutical Distribution
Tilray’s Global Beverage Business Delivers $101 Million in Revenue, Expands Gross Margin to 41% and BrewDog Achieves Profitability in Q1
Reduced Outstanding Debt by $42 Million Fiscal Year-to-Date and Ended the Q1 with a Net Cash1 Position, Strengthening Financial Flexibility and the Balance Sheet
Tilray Reaffirms Fiscal 2027 Adjusted EBITDA3 Guidance of $68 Million to $75 Million
NEW YORK and LONDON and LEAMINGTON, Ontario, Oct. 08, 2026 — Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company with leading positions across cannabis, beverage, hospitality and wellness, today reported financial results for its first fiscal quarter ended August 31, 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, stated: “Tilray’s record first-quarter revenue and gross profit demonstrate the power of the diversified platform we have built and the momentum we are creating across cannabis, beverage, hospitality, wellness and pharmaceutical distribution. We are no longer dependent on a single market or regulatory catalyst. We have multiple engines of growth, a scaled international footprint and the ability to convert scale into stronger margins, greater efficiency and sustainable, profitable growth.”
READ MORE
|
Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
INFARMED approval authorizes Tilray Medical’s Cantanhede, Portugal facility to conduct microbiological and chemical/physical testing on-site, advancing pharmaceutical-grade quality control within its EU-GMP production platform
CANTANHEDE, Portugal, Oct. 13, 2026 — Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal’s National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.
With this authorization, Tilray Medical further differentiates its European production platform by embedding advanced testing capabilities directly within its EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic center for cultivation, production, testing, and international supply, and comes as demand for trusted, pharmaceutical-grade medical cannabis continues to grow across regulated markets.
READ MORE
|
HEMP LAW UPDATE: BEFORE CURRENT PROPOSAL
A massive federal hemp-THC ban is scheduled to take effect on November 12, 2026. Signed into law as part of the FY2026 Agriculture Appropriations Act, it redefines legal hemp to a 0.3% total THC limit (inclusive of THCA and delta-8) and caps final-form cannabinoid products at 0.4 mg of THC per container, rendering about 95% of current hemp-derived products federally unlawful. The situation remains highly fluid at both the federal and state levels: Federal Updates
The Ban Scope: The impending rules prohibit synthetic cannabinoids and those "synthesized or manufactured outside the plant," which directly impacts popular products like delta-8 THC, HHC, and most THCA flower.
White House Pushback: The White House has actively urged Congress to either delay the November 2026 implementation date or pass a fair regulatory framework to preserve access to full-spectrum CBD products.
Legislative Push: Various lawmakers, including Rep. Andy Barr, have pushed proposals to establish a legal regulatory pathway for domestic consumer hemp, though its fate remains undecided. State-Level & Local Enforcement
Texas Ban: Following a state Supreme Court ruling, Texas will start enforcing strict rules on July 31, 2026, effectively reclassifying and banning common consumer hemp derivatives (like delta-8 and THCP) from state shelves.
Missouri Lawsuit: Ahead of the November federal changes, Missouri enacted a state-level ban on intoxicating hemp products that is actively being challenged in federal court by hemp coalitions. Other States: States like New Jersey and Minnesota are actively passing legislation attempting to tightly integrate hemp products into their existing licensed, regulated cannabis frameworks. FLORIDA:
Florida's hemp market faces a massive collapse as the November 12, 2026, federal ban collides with intense local political maneuvering, strict state-level packaging rules, and a locked recreational cannabis market.
Because Florida's popular hemp-THC products currently average 1 to 10 milligrams of THC per container (such as those sold at mainstream retailers), the upcoming federal 0.4 mg cap is projected to eliminate nearly the entire state hemp sector. Political Battles and Veto History Past Governor Veto: Governor Ron DeSantis previously vetoed a strict state-level hemp ban, warning it would cause "dramatic disruption and harm" to small retail businesses.
Senate-House Deadlocks: During legislative sessions, lawmakers introduced bills like SB 438 to create 50 mg package caps. However, the House and Senate failed to agree on distribution rules, causing the state-level caps to die on the floor.
Federal Lobbying: Desperate to survive the impending November 2026 cliff, Florida hemp businesses are heavily lobbying Capitol Hill and pinning their remaining hopes on the Trump administration delaying the rule or amending the 0.4 mg cap. Both Florida Senators, Rick Scott and Marco Rubio, originally voted in favor of the federal restrictions.
Current State Rules & Active Enforcement
Total THC Testing Rules: The Florida Department of Agriculture and Consumer Services (FDACS) successfully defended its strict testing formula in court. Florida officially calculates compliance using Total THC (Delta-9 + 0.877 × THCA), rendering THCA flower highly restricted even before the federal ban hits.
Packaging Crackdown: State rules aggressively target and seize products featuring cartoon imagery or bright packaging. All items must utilize strict child-resistant locking mechanisms and include visible QR codes linking to official Certificates of Analysis (COAs).
Age Restrictions: Under active laws, you must be 21 or older to buy any ingestible or inhalable hemp extract. Newer 2026 legislation explicitly targets THC-infused beverages under the 21+ restriction.
The Broader Cannabis Landscape
The hemp industry's desperation is magnified by the status of traditional cannabis in the state. The Florida Supreme Court officially blocked the adult-use marijuana legalization initiative from the 2026 ballot due to a failure to meet signature verification rules. Because recreational cannabis remains completely dead for the 2026 cycle, hemp businesses cannot easily transition into state-licensed recreational dispensaries. Instead, the state's commercial market remains restricted to its tightly controlled, corporate medical marijuana registry.
|
Trump-Backed Hemp Bill Could Replace the Federal THC Ban With Actual Regulation
Posted in HEMP NEWS by Carlos Hermida
A new bipartisan bill would regulate and tax hemp-derived THC products instead of effectively banning most of them in November. For consumers, farmers and small businesses, that is a much better conversation to be having.
JULY 26, 2026 – Congress may have discovered a strange new idea: if adults are buying a popular product, perhaps the government should regulate it instead of banning almost all of it and acting surprised when an illegal market appears.
On July 22, 2026, Republican Rep. Andy Barr of Kentucky and Democratic Rep. Angie Craig of Minnesota introduced the Lawful Hemp Protection Act, also identified as H.R. 9830. The bill has support from the Trump administration and would create a federal regulatory system for consumable hemp products, including some hemp-derived THC products.
The proposal arrives just months before a major change in federal law is scheduled to take effect on November 12, 2026. Unless Congress acts, the new federal definition of hemp will impose a limit of just 0.4 milligrams of total THC per container and prohibit certain synthesized or non-naturally occurring cannabinoids. In practice, that could remove a huge portion of today’s hemp-derived cannabinoid products from the legal market.
The Lawful Hemp Protection Act would take a different approach: establish rules, require testing, restrict sales to adults, collect taxes and punish irresponsible operators.
In other words, regulate the industry like grown-ups.
READ MORE
|
BELOW ARE THE LINKS TO THE DIRECTORY OF FLORIDA CANNABIS DOCTORS AND DISPENSARIES IN THE STATE OF FLORIDA |
QUALIFIED PATIENTS
OVER 942,000
AND 782 DISPENSING LOCATIONS |
LATEST OMMU REPORTS FROM OFFICE OF MEDICAL MARIJUANA USE IN THE STATE OF FLORIDA Highlights from
OCTOBER 9 2026 Report BY THE NUMBERS
Qualified Patients: (Active ID Card) OCT 09, 2026- 942,370 OCT 02, 2026- 941,963 SEP 25,2026- 941,616
SEP 18, 2026- 941, 650 SEP 11,2026- 941,271
SEP 04, 2026- 941,509
Patients Last Week: +407
Qualified Ordering Physicians: 2,032
New Doctors Last Week: 0 Reporting Period: OCT 2, 2026 - OCT 8, 2026
Amount of Medical Marijuana Dispensed - (mgs THC) 433,600,281
Amount of Low-THC Cannabis Dispensed - (mgs CBD) 908
Amount of Marijuana in a From for Smoking (oz) 154,879.642
Approved Dispensing Locations: 782 Added Last Week: 0 |
UPCOMING MEETING AND CONFERENCES |
ADVERTISEMENT OPPORTUNITIES
If your goal is to get your business in front of the right people in the cannabis industry or you want to be an integral part of this new and exciting business opportunity, then you need to join with Cannabis News Florida as we help to establish cannabis as a major part of the economy in Florida. Cannabis News Florida is an online publication focusing on both local and national news from leading authorities about the medical and business developments in the medical cannabis industry covering the entire state of Florida.
Join the Cannabis News Florida force online and in print. We offer several marketing options to fit all budgets:
· MMTC PROMOS LISTED IN EACH E-NEWSLETTER
• Directory Listing
• Banner Ads
• Ad Space in the Newspaper
• Feature Articles
• Weekly Newsletters
For further information or to make your ad reservation, please call:561-368-6950 / 954-605-4785 cell charles@cannabisnewsflorida.com
|
|
|
|